Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPensionProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Cash & Equivalents (2016 - 2025)

Fresenius Medical Care AG (FMS) has 16 years of Cash & Equivalents data on record, last reported at $1.9 billion in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 108.04% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, up 108.04%, while the annual FY2025 figure was $1.8 billion, 99.35% up from the prior year.
  • Cash & Equivalents reached $1.9 billion in Q4 2025 per FMS's latest filing, up from $894.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.9 billion in Q4 2025 and bottomed at $894.8 million in Q4 2024.
  • Average Cash & Equivalents over 4 years is $1.3 billion, with a median of $1.3 billion recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: crashed 45.16% in 2022, then surged 108.04% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $1.7 billion in 2021, then plummeted by 45.16% to $929.5 million in 2022, then fell by 3.73% to $894.8 million in 2024, then soared by 108.04% to $1.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $1.9 billion in Q4 2025, $894.8 million in Q4 2024, and $929.5 million in Q4 2022.